$4M Follow-On Offering Priced at $0.71 per Share
Event summary
- Aethlon Medical priced a $4M follow-on offering of 5.63M shares at $0.71 per share, including warrants.
- Proceeds will fund R&D, clinical trials, and potential acquisitions.
- Closing expected July 7, 2026, subject to customary conditions.
- Warrants exercisable post-stockholder approval, expiring five years later.
The big picture
Aethlon’s $4M offering reflects the cash burn typical of clinical-stage biotechs. The proceeds could accelerate Hemopurifier trials, but dilution risks loom at a time when investors scrutinize runway. Maxim Group’s role underscores reliance on specialized underwriters for niche medical devices.
What we're watching
- Capital Deployment
- How Aethlon allocates proceeds will signal priorities between R&D, trials, and acquisitions.
- Market Reception
- Whether the $0.71 share price stabilizes or triggers further volatility.
- Clinical Milestones
- The pace of Hemopurifier trial progress given increased funding.
Related topics